2011
The impact of the coronary collateral circulation on mortality: a meta-analysis
Meier P, Hemingway H, Lansky AJ, Knapp G, Pitt B, Seiler C. The impact of the coronary collateral circulation on mortality: a meta-analysis. European Heart Journal 2011, 33: 614-621. PMID: 21969521, DOI: 10.1093/eurheartj/ehr308.Peer-Reviewed Original ResearchConceptsCoronary artery diseaseStable coronary artery diseaseCoronary collateral circulationMyocardial infarctionCollateral circulationRisk ratioHigh collateralizationLow collateralizationSummary risk ratiosAcute myocardial infarctionSubacute myocardial infarctionRandom-effects modelRelevant protective effectCause mortalityCoronary collateralsHard endpointsArtery diseaseCoronary collateralizationVentricular remodellingInfarct sizeClinical endpointsBlood supplyProtective effectMortality riskPatients
2010
Mesh covered stent in ST-segment elevation myocardial infarction.
Dudek D, Dziewierz A, Rzeszutko Ł, Legutko J, Dobrowolski W, Rakowski T, Bartus S, Dragan J, Klecha A, Lansky AJ, Siudak Z, Zmudka K. Mesh covered stent in ST-segment elevation myocardial infarction. EuroIntervention 2010, 6: 582-9. PMID: 21044911, DOI: 10.4244/eijv6i5a98.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionPercutaneous coronary interventionElevation myocardial infarctionDistal embolisationMyocardial infarctionTotal major adverse cardiac events rateFinal TIMI grade 3 flowMajor adverse cardiac event ratesAdverse cardiac event ratesMyocardial blush grade 3Primary percutaneous coronary interventionTIMI grade 3 flowCardiac event rateGrade 3 flowSingle-arm studySTEMI patientsCoronary interventionThrombus aspirationArm studyStent implantationClinical endpointsGrade 3PatientsClinical feasibilityEvent ratesThe relative effects of abciximab and tirofiban on platelet inhibition and C-reactive protein during coronary intervention.
Saltzman AJ, Mehran R, Hooper WC, Moses JW, Weisz G, Collins MB, Lansky AJ, Kreps EM, Leon MB, Stone GW, Dangas G. The relative effects of abciximab and tirofiban on platelet inhibition and C-reactive protein during coronary intervention. Journal Of Invasive Cardiology 2010, 22: 2-6. PMID: 20048389.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAngina, UnstableAngioplasty, Balloon, CoronaryAntibodies, MonoclonalBlood PlateletsC-Reactive ProteinDose-Response Relationship, DrugDouble-Blind MethodDrug Therapy, CombinationFemaleHeparinHumansImmunoglobulin Fab FragmentsMaleMiddle AgedPilot ProjectsPlatelet AggregationPlatelet Aggregation InhibitorsStentsTime FactorsTirofibanTyrosineConceptsPercutaneous coronary interventionC-reactive proteinTarget vessel revascularizationPlatelet inhibitionCoronary interventionLevels of CRPInflammatory markers C-reactive proteinPlatelet aggregationC-reactive protein levelsDouble-blind study designEfficacy of tirofibanLower platelet inhibitionCoronary artery bypassCoronary artery revascularizationArtery revascularizationDiabetic subsetEligible patientsNonfatal MIArtery bypassHs-CRPVessel revascularizationSpearman correlation coefficient modelClinical endpointsFirst time pointTirofiban